GLP-1 Agonists
Sort by:
UPMC
Update on Metabolic-dysfunction Associated Steatotic Liver Disease
FEATURING
Tinsay Woreta
- 723 views
- February 3, 2024
- 8
University of Louisville
Type 3C Diabetes: Update
FEATURING
Sri Prakash Mokshagundam
- 56 views
- February 1, 2024
Susan Brian
The Differences Between the Products of GLP1's and GLP/GIPs
- 2,104 views
- January 29, 2024
- 36
Susan Brian
Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist
- 2,149 views
- January 26, 2024
- 40
The Texas Heart Institute
Antihyperglycemic Medications for CV Risk Reduction: a Cardiologist's Perspective
FEATURING
Darren K. Mcguire
- 1,230 views
- January 18, 2024
- 10
Icahn School of Medicine at Mount Sinai
Diagnosis and Treatment of Abnormal Growth: Recommendations and Novel Solutions
FEATURING
Cheri Deal
- 464 views
- January 4, 2024
- 4
NYU Langone
Autoantibodies & Diabetes Screening, and the Advances in Novel Therapies
FEATURING
Michael Natter
- 479 views
- December 15, 2023
- 6
Houston Methodist Hospital
The Role of MRAs and ERAs in Delaying CKD Progression
FEATURING
Rajiv Agarwal
- 972 views
- December 12, 2023
- 6
Michigan Medicine
How and When To Treat Fatty Liver Disease
FEATURING
Vincent Chen
- 1,432 views
- December 9, 2023
- 7
Scripps Health
Annual Diabetes Updates - 2023
FEATURING
Athena Tsimikas
- 261 views
- December 8, 2023
- 1
Jefferson Health
Beyond Glycemic Control: A New Paradigm in T2D Management
FEATURING
Intekhab Ahmed
- 1,063 views
- December 8, 2023
- 6
Keck School of Medicine of USC
Heterogeneity and Therapy Options for T2D: Q&A Discussion
FEATURING
Anne Peters,
Nairi Berner
- 8 views
- November 30, 2023
Keck School of Medicine of USC
Care for Patients with Diabetes in Resource-Limited Settings
FEATURING
Mojdeh Moradi
- 73 views
- November 30, 2023
- 1
Keck School of Medicine of USC
Should Obesity Be the Treatment Target in Type 2 Diabetes?
FEATURING
Jaime Almandoz
- 498 views
- November 30, 2023
- 4
15th Annual Orange County Symposium for Cardiovascular Disease Prevention
Reducing Cardiometabolic Risk with SGLT2i and GLP1-RA – How to Choose and in Who
FEATURING
Qin Yang
- 946 views
- November 24, 2023
- 5
AHA 2023 Insights
AHA 2023 Insights: Estimated Lifetime Benefits of SGLT2i, GLP-1 RA and ns-MRA in People with Type 2 Diabetes and Albuminuria
FEATURING
Brendon Neuen
- 178 views
- November 23, 2023
- 2
Jefferson Health
Diabesity: New Trends in Management
FEATURING
Kevin Furlong
- 826 views
- November 23, 2023
- 11
AHA 2023 Insights
AHA 2023 Insights: Reflections on SELECT Trial
FEATURING
Donna Ryan
- 2,070 views
- November 21, 2023
- 11
AHA 2023 Insights
AHA 2023 Insights: GLP1-RAs - Clinical Indications and Cardiovascular Benefits
FEATURING
Naveed Sattar
- 328 views
- November 21, 2023
Penn Medicine Heart and Vascular Center
Treatments for CV Risk Reduction: Clinical Case Discussion
- 86 views
- November 21, 2023
- 1